TPD52L2 and prostate adenocarcinoma: The results shown in Figure 2A, TPD52L2 was highly expressed in Kidney renal clear cell carcinoma, Kidney renal papillary cell carcinoma, Liver hepatocellular carcinoma, Bladder Urothelial Carcinoma, Breast invasive carcinoma, Cholangio carcinoma, Colon adenocarcinoma, Esophageal carcinoma, Head and Neck squamous cell carcinoma, Lung adenocarcinoma, Lung squamous cell carcinoma, Rectum adenocarcinoma, and Stomach adenocarcinoma; TPD52L2 was low expressed in Kidney Chromophobe and Prostate adenocarcinoma.